Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 17/20 | 0.57 |
| ▸ | BCAT1 | P54687 | 17/20 | 0.57 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7681836 | 0.82 | BCAT1 (0.42) | BCAT2BCAT1CYP1A2MAPTALOX15 | |
| SCHEMBL24826936 | 0.82 | BCAT1 (0.62) | BCAT2BCAT1 | |
| SCHEMBL29779349 | 0.82 | BCAT1 (0.62) | BCAT2BCAT1 | |
| SCHEMBL8188639 | 0.81 | BCAT2 (0.61) | BCAT2BCAT1 | |
| SCHEMBL7038819 | 0.78 | BCAT1 (0.72) | BCAT2BCAT1 | |
| SCHEMBL8697055 | 0.78 | SMN1; SMN2 (0.48) | BCAT2BCAT1CYP1A2MAPT | |
| SCHEMBL8776052 | 0.77 | VCAM1 (0.47) | BCAT2BCAT1VCAM1CYP1A2MAPT | |
| SCHEMBL6920290 | 0.76 | VCAM1 (0.41) | BCAT2BCAT1VCAM1CYP1A2MAPT | |
| SCHEMBL7959029 | 0.75 | BCAT1 (0.59) | BCAT2BCAT1 | |
| SCHEMBL6815503 | 0.75 | BCAT1 (0.54) | BCAT2BCAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656884-B2 | Use as herbicides or for the desiccation or defoliation of plants | BASF AKTIENGESELLSCHAFT (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20030181335-A1 | Novel 3- (4-cyanophenyl) uracils | KLINTZ RALF (DE) | 2003-09-25 | — | — | US | disclosed |
| EP-0808310-B1 | 3-(4-CYANOPHENYL)URACILS | BASF AG (DE) | 2002-01-02 | — | — | EP | disclosed |
| EP-0808310-A1 | NOVEL 3-(4-CYANOPHENYL)URACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996024590-A1 | NOVEL 3-(4-CYANOPHENYL)URACILS | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181335-A1 | Novel 3- (4-cyanophenyl) uracils | CBR1, CBR3, AOC3 | BCAT2 1421/4885BCAT1 555/4885VCAM1 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.